Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $42.70

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $42.70.

Several research analysts recently weighed in on KYMR shares. Piper Sandler lifted their price target on Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Oppenheimer reduced their price target on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Truist Financial raised their price objective on Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a report on Monday.

Read Our Latest Stock Report on KYMR

Kymera Therapeutics Stock Down 1.9 %

Shares of NASDAQ:KYMR opened at $31.20 on Wednesday. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $45.31. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -12.43 and a beta of 2.25. The business has a 50-day moving average price of $34.77 and a 200-day moving average price of $33.82.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. Kymera Therapeutics’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the business earned ($0.70) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics will post -2.86 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joanna Horobin sold 8,500 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in Kymera Therapeutics during the fourth quarter worth $78,000. Comerica Bank boosted its stake in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after buying an additional 295 shares during the last quarter. Virtu Financial LLC acquired a new position in Kymera Therapeutics during the first quarter worth $207,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after buying an additional 5,002 shares during the last quarter.

About Kymera Therapeutics

(Get Free Report

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Further Reading

Analyst Recommendations for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.